$NVFY
Nova Lifestyle, Inc. Stock $nvfy

$nvfy Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022349 Filed on August 12, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$3.016M	$3.813M	$3.666M
YoY Change	3.41%	7.41%	10.09%
Cost Of Revenue	$1.878M	$7.361M	$2.138M
YoY Change	23.82%	-2.59%	9.62%
Gross Profit	$1.138M	-$3.548M	$1.528M
YoY Change	-18.71%	-11.45%	10.75%
Gross Profit Margin	37.72%	-93.05%	41.69%
Selling, General & Admin	$2.092M	$2.135M	$2.348M
YoY Change	-14.31%	-6.03%	9.72%
% of Gross Profit	183.85%		153.64%
Research & Development	$660.00	$1.005K	$8.660K
YoY Change	-99.37%	-34.18%
% of Gross Profit	0.06%		0.57%
Depreciation & Amortization	$19.95K	$20.31K	$21.86K
YoY Change	-15.22%	-2.26%	9.3%
% of Gross Profit	1.75%		1.43%
Operating Expenses	$2.092M	$2.135M	$2.357M
YoY Change	-17.85%	-6.03%	9.62%
Operating Profit	-$954.0K	-$5.683M	-$828.4K
YoY Change	-16.82%	-9.49%	7.59%
Interest Expense	-$759.1K	-$8.800K	-$33.08K
YoY Change	822.78%	-86.15%	-430.8%
% of Operating Profit
Other Income/Expense, Net	-$759.0K	-$8.791K	-$47.55K
YoY Change		-86.16%
Pretax Income	-$1.713M	-$5.692M	-$898.1K
YoY Change	39.37%	-10.26%	19.74%
Income Tax
% Of Pretax Income
Net Earnings	-$1.713M	-$5.692M	-$898.1K
YoY Change	22.65%	-10.31%	18.16%
Net Earnings / Revenue	-56.79%	-149.26%	-24.5%
Basic Earnings Per Share	-$0.25	-$0.83	-$0.13
Diluted Earnings Per Share	-$247.1K	-$827.6K	-$131.2K
COMMON SHARES
Basic Shares Outstanding	6.882M shares	6.877M shares	6.846M shares
Diluted Shares Outstanding	1.387M shares	1.375M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.170M	$4.683M	$5.368M
YoY Change	-59.76%	-14.94%	-29.74%
Cash & Equivalents	$3.170M	$4.683M	$5.368M
Short-Term Investments
Other Short-Term Assets	$352.2K	$709.2K	$615.6K
YoY Change	-59.23%	-13.98%	36.8%
Inventory	$12.76M	$13.47M	$18.69M
Prepaid Expenses	$309.4K	$406.5K
Receivables	$389.9K	$208.3K	$289.5K
Other Receivables	$30.25K	$26.38K	$351.4K
Total Short-Term Assets	$16.70M	$19.10M	$25.32M
YoY Change	-55.29%	-46.78%	-39.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$383.4K	$414.8K	$3.417M
YoY Change	-84.44%	-83.31%	34.02%
Goodwill	$218.6K	$218.6K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$69.73K	$71.10K	$72.46K
YoY Change	-3.91%	-2.39%	-61.86%
Total Long-Term Assets	$3.392M	$3.473M	$3.708M
YoY Change	23.13%	25.09%	25.29%
TOTAL ASSETS
Total Short-Term Assets	$16.70M	$19.10M	$25.32M
Total Long-Term Assets	$3.392M	$3.473M	$3.708M
Total Assets	$20.10M	$22.57M	$29.03M
YoY Change	-49.91%	-41.62%	-35.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$928.5K	$376.0K	$681.9K
YoY Change	29.58%	-31.63%	39.16%
Accrued Expenses	$955.9K	$1.021M	$1.221M
YoY Change	-0.4%	3.66%	32.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.211M	$2.166M	$2.288M
YoY Change	-5.84%	-1.48%	57.82%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0K	$150.0K	$150.0K
YoY Change	0.0%	0.0%	0.0%
Other Long-Term Liabilities	$3.294M	$3.380M	$3.945M
YoY Change	14.26%	18.24%	22.89%
Total Long-Term Liabilities	$3.444M	$3.530M	$4.095M
YoY Change	13.55%	17.33%	21.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.211M	$2.166M	$2.288M
Total Long-Term Liabilities	$3.444M	$3.530M	$4.095M
Total Liabilities	$5.656M	$5.696M	$6.383M
YoY Change	5.09%	9.39%	32.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$27.91M	-$26.19M
YoY Change
Common Stock	$43.15M	$42.98M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.44M	$16.87M	$22.64M
YoY Change
Total Liabilities & Shareholders Equity	$20.10M	$22.57M	$29.03M
YoY Change	-49.91%	-41.62%	-35.15%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.713M	-$5.692M	-$898.1K
YoY Change	22.65%	-10.31%	18.16%
Depreciation, Depletion And Amortization	$19.95K	$20.31K	$21.86K
YoY Change	-15.22%	-2.26%	9.3%
Cash From Operating Activities	-$2.132M	-$465.3K	-$856.6K
YoY Change	40.75%	-36.68%	-2.66%
INVESTING ACTIVITIES
Capital Expenditures	-$4.280K	-$1.490K
YoY Change	93.67%	-99.03%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$4.280K	-$1.490K
YoY Change	-100.35%	-99.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-2.132M	-465.3K	-856.6K
Cash From Investing Activities	-4.280K	-1.490K
Cash From Financing Activities	0.000
Net Change In Cash	-2.136M	-466.8K	$0.00
YoY Change	-186.67%	-77.86%
FREE CASH FLOW
Cash From Operating Activities	-$2.132M	-$465.3K	-$856.6K
Capital Expenditures	-$4.280K	-$1.490K
Free Cash Flow	-$2.127M	-$463.8K
YoY Change	40.67%	-20.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001473334
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable		usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	NVFY	Deregistration And Liquidation Of Closed Subsidiary Nova Macau DeregistrationAndLiquidationOfClosedSubsidiaryNovaMacau		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
	NVFY	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36259
	dei	Entity Registrant Name EntityRegistrantName	NOVA LIFESTYLE, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0746568
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6565 E. Washington Blvd
	dei	Entity Address City Or Town EntityAddressCityOrTown	Commerce
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90040
	dei	City Area Code CityAreaCode	(323)
	dei	Local Phone Number LocalPhoneNumber	888-9999
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	NVFY
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6882021	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4682698	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6276106	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	208255	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	103397	usd
CY2022Q2	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	302721	usd
CY2021Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	707264	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	13469887	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	17656175	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	406457	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	406366	usd
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	26376	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	120634	usd
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	299011	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	19096394	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	25568953	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	414810	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	510680	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2768825	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3158734	usd
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	71100	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	72651	usd
CY2022Q2	us-gaap	Goodwill Goodwill	218606	usd
CY2021Q4	us-gaap	Goodwill Goodwill	218606	usd
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	3473341	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3960671	usd
CY2022Q2	us-gaap	Assets Assets	22569735	usd
CY2021Q4	us-gaap	Assets Assets	29529624	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	375976	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	358362	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	701661	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	731284	usd
CY2022Q2	NVFY	Advance From Customers Current AdvanceFromCustomersCurrent	344139	usd
CY2021Q4	NVFY	Advance From Customers Current AdvanceFromCustomersCurrent	394376	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	537008	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	326679	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	2149	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	3696	usd
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	204847	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2165780	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1814397	usd
CY2022Q2	us-gaap	Other Loans Payable OtherLoansPayable	150000	usd
CY2021Q4	us-gaap	Other Loans Payable OtherLoansPayable	150000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2222349	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2577567	usd
CY2022Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	1157604	usd
CY2021Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	1543472	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3529953	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4271039	usd
CY2022Q2	us-gaap	Liabilities Liabilities	5695733	usd
CY2021Q4	us-gaap	Liabilities Liabilities	6085436	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6891313	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6891313	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6836742	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6836742	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	6892	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6837	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	42974288	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	42660383	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	87258	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	381850	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26194436	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19604882	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16874002	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23444188	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22569735	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29529624	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7478993	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6881583	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3813047	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3550016	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13061	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3385	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6589554	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7109064	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5691507	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-6345527	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-294592	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-392764	usd
	us-gaap	Cost Of Revenue CostOfRevenue	9498842	usd
	us-gaap	Cost Of Revenue CostOfRevenue	9508404	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	7361224	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	7557149	usd
	us-gaap	Gross Profit GrossProfit	-2019849	usd
	us-gaap	Gross Profit GrossProfit	-2626821	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	-3548177	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	-4007133	usd
	us-gaap	Selling Expense SellingExpense	1538544	usd
	us-gaap	Selling Expense SellingExpense	1646842	usd
CY2022Q2	us-gaap	Selling Expense SellingExpense	770211	usd
CY2021Q2	us-gaap	Selling Expense SellingExpense	878757	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2952737	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2771043	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1364328	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1392713	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-36549	usd
	us-gaap	Operating Expenses OperatingExpenses	4527830	usd
	us-gaap	Operating Expenses OperatingExpenses	4417885	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2134539	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	2271470	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6547679	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7044706	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5682716	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6278603	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	63644	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	34428	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	45881	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-34556	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-5959	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	25911	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2885	usd
CY2021Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	28301	usd
	NVFY	Financial Expenses FinancialExpenses	99560	usd
	NVFY	Financial Expenses FinancialExpenses	111636	usd
CY2022Q2	NVFY	Financial Expenses FinancialExpenses	51787	usd
CY2021Q2	NVFY	Financial Expenses FinancialExpenses	57284	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-41875	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-51297	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8791	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-63539	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6589554	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7096003	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5691507	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6342142	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-239719	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-163917	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6884146	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7501828	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5931226	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6509444	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6860907	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5601988	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6876963	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5605261	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.27
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	22642600	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3300	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	159328	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-239719	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5691507	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16874002	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	39948961	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2970	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	9900	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-163917	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-6345527	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	33452387	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23444188	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	6600	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	307360	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-294592	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6589554	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16874002	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	40928475	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	5940	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	19800	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-392764	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7109064	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	33452387	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6589554	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7109064	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	42161	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38526	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	378403	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	385816	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-36549	usd
	us-gaap	Inventory Write Down InventoryWriteDown	5119054	usd
	us-gaap	Inventory Write Down InventoryWriteDown	5526307	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	313960	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	25740	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1060	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-3590	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	105918	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-359078	usd
	us-gaap	Increase Decrease In Materials And Supplies IncreaseDecreaseInMaterialsAndSupplies	-404543	usd
	us-gaap	Increase Decrease In Materials And Supplies IncreaseDecreaseInMaterialsAndSupplies	-62921	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	932766	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-124171	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-86299	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	703768	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-370841	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-363836	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	17614	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-193852	usd
	NVFY	Increase Decrease In Advance From Customers IncreaseDecreaseInAdvanceFromCustomers	-50237	usd
	NVFY	Increase Decrease In Advance From Customers IncreaseDecreaseInAdvanceFromCustomers	-3777	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	209791	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	421366	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	117990	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-180832	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1321892	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1614794	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1220226	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1487	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	152950	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1487	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1373176	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-270029	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-251665	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1593408	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3239635	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6276106	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8744784	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4682698	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5505149	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	42102	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	193948	usd
	us-gaap	Interest Paid Net InterestPaidNet	8013	usd
	us-gaap	Interest Paid Net InterestPaidNet	2910	usd
CY2020Q1	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	2500000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_ziwyyVL3pTvh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In preparing consolidated financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the dates of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include, but are not limited to, revenue recognition, the allowance for bad debt, valuation of inventories, the valuation of stock-based compensation, income taxes and unrecognized tax benefits, valuation allowance for deferred tax assets, assumptions used in assessing impairment of long-lived assets and goodwill, and loss contingencies. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The COVID-19 pandemic has created and may continue to create significant uncertainty in macroeconomic conditions, which may cause further business slowdowns or shutdowns, supply chain disruption, depress demand for the Company’s products, and adversely impact its results of operations. During the six months ended June 30, 2022, the Company continued to face increasing uncertainties around its estimates of revenue collectability, accounts receivable credit losses and valuation of inventories. The Company expects uncertainties around its key accounting estimates to continue to evolve depending on the duration and degree of impact associated with the COVID-19 pandemic. Its estimates may change as new events occur and additional information emerges, and such changes are recognized or disclosed in its unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	26700000	usd
CY2021Q4	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	26700000	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2021Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	900	usd
CY2021Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	900	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1044	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1060	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2104	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1060	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-3590	usd
CY2022Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-820	usd
CY2021Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-130	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9668	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4791	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1005	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1527	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13061	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3385	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	935	usd
CY2021Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	14	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2021Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	7	usd
	us-gaap	Advertising Expense AdvertisingExpense	619673	usd
	us-gaap	Advertising Expense AdvertisingExpense	823947	usd
CY2022Q2	us-gaap	Advertising Expense AdvertisingExpense	321541	usd
CY2021Q2	us-gaap	Advertising Expense AdvertisingExpense	416085	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6589554	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7109064	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5691507	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-6345527	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6860907	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5601988	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6876963	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5605261	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.27
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	42779	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	42779	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_z3RktT4MHCB4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Concentration of Credit Risk</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial instruments that potentially subject the Company to credit risk consist primarily of accounts and other receivables. The Company does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">No customer accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zsZGBnAvAl5i"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_ztT3XDt7QDs6"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210401__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zGEM2Pykbe5g"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zhZmZY6FYUq9">10</span></span></span></span>% or more of the Company’s sales for the six and three months ended June 30, 2022 and 2021. Three customers accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zsIlZOJUozz1" title="Concentration risk percentage">36</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmhswbesPpy8" title="Concentration risk percentage">23</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThreeCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOQGfPJRRQnf" title="Concentration risk percentage">17</span>%, respectively, of the Company’s gross accounts receivable as of June 30, 2022. Four customers accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYP6TP8jWA9h" title="Concentration risk percentage">22</span>%, <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zM6cln5XGtgg" title="Concentration risk percentage">19</span>%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThreeCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zjHSGdgcb0qe" title="Concentration risk percentage">14</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FourCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBPyQX8H75Qb" title="Concentration risk percentage">14</span>%, respectively, of the Company’s gross accounts receivable as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company purchased its products from three major vendors during the six months ended June 30, 2022 and 2021, respectively, accounting for a total of <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeVendorsMember_zgIRqU8xaEoa" title="Concentration risk percentage">53</span>% for 2022 (<span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_z3jpITpqpmo8" title="Concentration risk percentage">22</span>%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zMgdDr06hdv1" title="Concentration risk percentage">21</span>%, and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember_z1nAxxdp4ui9" title="Concentration risk percentage">10</span>%) and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeVendorsMember_z5yetbo7eBo5" title="Concentration risk percentage">59</span>% for 2021 (<span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_z7O318UFI2d9" title="Concentration risk percentage">32</span>%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zPRWTc56CFQ7" title="Concentration risk percentage">16</span>%, and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember_ziWoR4xva925" title="Concentration risk percentage">11</span>% each) of the Company’s purchases. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company purchased its products from two major vendors during the three months ended June 30, 2022 and 2021, accounting for a total of <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoVendorsMember_zD1LdIE1NItj">41</span>% for 2022 (<span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zzLa2mr83Y28">26</span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zDnGj8PjP57k" title="Concentration risk percentage">15</span>%) and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210401__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoVendorsMember_zt3rF7u6NMYc" title="Concentration risk percentage">51</span>% for 2021 (<span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210401__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zlD2W3uGsCSc" title="Concentration risk percentage">33</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210401__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zWgSnjMlVyS4" title="Concentration risk percentage">18</span>%) of the Company’s purchases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances made to these vendors were $<span style="background-color: white"><span id="xdx_90D_ecustom--AdvancesToSuppliers_iI_c20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zYn19w0IuhK8" title="Advances made to suppliers">150,162</span></span> and $<span id="xdx_90A_ecustom--AdvancesToSuppliers_iI_c20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zErO0by2mEPk">307,718</span> as of June 30, 2022 and December 31, 2021, respectively. Accounts payable to these vendors were $<span style="background-color: white"><span id="xdx_902_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pp0p0_c20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zYGt7hG7KVdk" title="Accounts payable to suppliers">204,829</span></span> and $<span id="xdx_902_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zXfWmm7XZXn3" title="Accounts payable to suppliers">125,636</span> as of June 30, 2022 and December 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Inventory Net InventoryNet	13469887	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	17656175	usd
	us-gaap	Inventory Write Down InventoryWriteDown	5119054	usd
CY2022Q2	us-gaap	Inventory Write Down InventoryWriteDown	5119054	usd
	us-gaap	Inventory Write Down InventoryWriteDown	5526307	usd
CY2021Q2	us-gaap	Inventory Write Down InventoryWriteDown	5526307	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1225959	shares
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	895587	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	961198	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	480777	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	450518	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	414810	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	510680	usd
	us-gaap	Depreciation Depreciation	42161	usd
	us-gaap	Depreciation Depreciation	38526	usd
CY2022Q2	us-gaap	Depreciation Depreciation	20306	usd
CY2021Q2	us-gaap	Depreciation Depreciation	20775	usd
CY2022Q2	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	302721	usd
CY2021Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	707264	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	537008	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	326679	usd
CY2020Q2	us-gaap	Proceeds From Loans ProceedsFromLoans	139802	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	406457	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	406366	usd
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	26376	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	120634	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	432833	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	527000	usd
CY2022Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	8609	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	6893	usd
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6346	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6231	usd
CY2022Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	211600	usd
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	134173	usd
CY2022Q2	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	94694	usd
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	66507	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	215759	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	112875	usd
CY2020Q2	us-gaap	Debt Instrument Description DebtInstrumentDescription	The loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. On June 5, 2020, Congress passed a new law that allowed current PPP borrowers to choose to extend the eight-week period to 24 weeks to use the funds, but which cannot be extended beyond December 31, 2020.
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1225959	shares
	NVFY	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice	3.50
CY2021Q4	NVFY	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.50
	NVFY	Share Based Weighted Average Remaining Contractual Term Outstanding ShareBasedWeightedAverageRemainingContractualTermOutstanding	P5Y7D
CY2022Q2	NVFY	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.50
	NVFY	Share Based Weighted Average Remaining Contractual Term Outstanding1 ShareBasedWeightedAverageRemainingContractualTermOutstanding1	P4Y6M7D
	NVFY	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable1	1225959	shares
	us-gaap	Operating Lease Cost OperatingLeaseCost	400376	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	428759	usd
	NVFY	Share Based Weighted Average Remaining Contractual Term Exercisable ShareBasedWeightedAverageRemainingContractualTermExercisable	P4Y6M7D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	340500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.97
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P1Y3M25D
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	340500	shares
CY2021Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.97
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P1Y3M25D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	340500	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.97
	NVFY	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm	P0Y9M25D
CY2022Q2	NVFY	Share Based Compensation Arrangement By Share Based Payment Awards Option Vested And Expected To Vest Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionVestedAndExpectedToVestExercisable	340500	shares
CY2022Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.97
	NVFY	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm	P0Y9M25D
CY2022Q2	NVFY	Intrinsic Value Off Stock Options IntrinsicValueOffStockOptions	0.72
	us-gaap	Revenues Revenues	7478993	usd
	us-gaap	Revenues Revenues	6881583	usd
CY2022Q2	us-gaap	Revenues Revenues	3813047	usd
CY2021Q2	us-gaap	Revenues Revenues	3550016	usd
CY2022Q2	us-gaap	Noncurrent Assets NoncurrentAssets	3183635	usd
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	3669414	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	213217	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	199582	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	396310	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	733806	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	703881	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	701142	usd
CY2022Q2	NVFY	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	598820	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3133959	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	209949	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2924010	usd
	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	423576	usd
	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	418694	usd
CY2018Q4	us-gaap	Loss Contingency Allegations LossContingencyAllegations	On December 28, 2018, a federal putative class action complaint was filed by George Barney against the Company and its former and current CEOs and CFOs (Thanh H. Lam, Ya Ming Wong, Jeffery Chuang and Yuen Ching Ho) in the United States District Court for the Central District of California, claiming the Company violated federal securities laws and pursuing remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 (the “Barney Action”). Richard Deutner and ITENT EDV were subsequently appointed as lead plaintiffs and, on June 18, 2019, filed an Amended Complaint.
CY2018Q4	us-gaap	Loss Contingency Actions Taken By Plaintiff LossContingencyActionsTakenByPlaintiff	Plaintiffs seek to represent a class of entities acquiring Nova’s stock from December 3, 2015 through December 20, 2018. They claim that during this period the Company: (1) overstated its purported strategic alliance with a customer in China to operate as lead designer and manufacturer for all furnishings in its planned $460 million senior care center in China; and (2) inflated sales in 2016 and 2017 by recognizing significant sales to two allegedly non-existent customers.
CY2022Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	750000	usd

Files In Submission

Name	View Source	Status
0001493152-22-022349-index-headers.html	Edgar Link	pending
0001493152-22-022349-index.html	Edgar Link	pending
0001493152-22-022349.txt	Edgar Link	pending
0001493152-22-022349-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvfy-20220630.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
nvfy-20220630_cal.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
nvfy-20220630_def.xml	Edgar Link	unprocessable
nvfy-20220630_lab.xml	Edgar Link	unprocessable
nvfy-20220630_pre.xml	Edgar Link	unprocessable
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVFY
Nova Lifestyle, Inc. Stock $nvfy

2022 Q3 Form 10-Q Financial Statement

#000149315222022349 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVFY Nova Lifestyle, Inc. Stock $nvfy

2022 Q3 Form 10-Q Financial Statement

#000149315222022349 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVFY
Nova Lifestyle, Inc. Stock $nvfy